INmune Bio (NASDAQ:INMB) Announces Quarterly Earnings Results

INmune Bio (NASDAQ:INMB) posted its earnings results on Thursday. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11), Zacks reports. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 121.57%. During the same period in the prior year, the business earned ($0.48) EPS.

INmune Bio Stock Up 3.2 %

Shares of INMB stock traded up $0.19 during trading hours on Friday, reaching $6.04. 225,027 shares of the company’s stock were exchanged, compared to its average volume of 228,751. INmune Bio has a fifty-two week low of $4.78 and a fifty-two week high of $14.74. The stock has a market capitalization of $119.35 million, a P/E ratio of -2.77 and a beta of 1.84. The business has a fifty day moving average price of $5.64 and a 200-day moving average price of $7.78.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Raymond James started coverage on INmune Bio in a report on Friday, September 27th. They set an “outperform” rating and a $18.00 price target on the stock. Scotiabank started coverage on shares of INmune Bio in a report on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 target price on the stock. Finally, Alliance Global Partners initiated coverage on shares of INmune Bio in a research report on Monday, October 21st. They set a “buy” rating and a $20.00 target price for the company.

Insider Transactions at INmune Bio

In related news, CFO David J. Moss acquired 7,690 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, with a total value of $49,062.20. Following the completion of the transaction, the chief financial officer now owns 1,275,869 shares of the company’s stock, valued at approximately $8,140,044.22. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CFO David J. Moss acquired 7,690 shares of the stock in a transaction dated Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the completion of the transaction, the chief financial officer now owns 1,275,869 shares in the company, valued at approximately $8,140,044.22. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO David J. Moss bought 10,000 shares of INmune Bio stock in a transaction that occurred on Monday, September 30th. The stock was purchased at an average cost of $5.29 per share, with a total value of $52,900.00. Following the completion of the transaction, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 33,070 shares of company stock worth $200,087. Insiders own 35.20% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.